Vir Biotechnology, Inc. Common Stock (VIR)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Vir Biotechnology, Inc. Common Stock (VIR) is listed on Nasdaq, where it has traded since October 11, 2019.
- Listed On
- Nasdaq
- Listed Since
- October 11, 2019
- Employees
- 367
- Market Cap
- $2.0B
About Vir Biotechnology, Inc. Common Stock
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 230 institutions reported holding VIR, with 146.6 million shares worth $1.5 billion in aggregate. The largest reported holder was BlackRock, with 20.7 million shares worth $210.7 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 20,678,283 | $211M | Added 14.89% |
| Vanguard | 18,903,886 | $193M | Added 21.94% |
| Arch Venture Management | 12,694,163 | $129M | Reduced 1.72% |
| SB Investment Advisers (UK) | 10,948,093 | $112M | Unchanged |
| State Street | 9,964,151 | $102M | Added 39.53% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is VIR?
Vir Biotechnology, Inc. Common Stock (VIR) is listed on Nasdaq, where it has traded since October 11, 2019.
Who are the largest institutional holders of VIR?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of VIR were BlackRock, Vanguard and Arch Venture Management.
How many institutions own VIR?
230 institutions reported a position in VIR for the quarter ended June 30, 2026, worth $1.5 billion in total.
Did institutions buy or sell VIR last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for VIR.
Every reported institutional holder, plus insider and congressional trades in VIR, on SentiSense.